PubMed
Afamelanotide for erythropoietic protoporphyria
Langendonk et al., 2015
Sexual HealthCaution: Indication-Specific ApprovalC
Melanotan I
Afamelanotide-related
Alpha-MSH analog related to afamelanotide pathways; non-indicated tanning use carries risk.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 99
- Activity
- 79
Overall check-ins
Trackers & reports
Overview
About Melanotan I
Alpha-MSH analog related to afamelanotide pathways; non-indicated tanning use carries risk.
- Category
- Sexual Health
- Regulatory status
- Caution: Indication-Specific Approval
- Also known as
- Afamelanotide-related
- Self-reports
- 26
Community
What 26 users report
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
159
Mood
159
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
2
Headache
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0.2 to ≥ 2 mg (open-ended top bucket)
0.2–0.4 mg
2
0.4–0.6 mg
12
0.6–1 mg
2
1–2 mg
46
2+ mg
97
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 127 days · Based on 25 repeat reporters
Research
Cited research (3)
Source
PubMed
Afamelanotide
Unknown, 2024
PubMed
Targeting the central melanocortin system for the treatment of metabolic disorders
Sweeney et al., 2023
Tools
Explore more
Explore
More ways to learn about Melanotan I from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Melanotan I?
This page summarizes 26 anonymized self-reports from PeptIQ users who track Melanotan I, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Melanotan I?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Melanotan I?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Melanotan I safe to use?
This wiki does not assess safety or recommend use. Melanotan I is listed as Caution: Indication-Specific Approval. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Melanotan I?
This wiki summarizes observational community reports and linked citations for Melanotan I. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Melanotan I for study-level context — not medical advice.
What is the legal status of Melanotan I?
Melanotan I is listed in PeptIQ as Caution: Indication-Specific Approval. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Melanotan I?
Safety data quality for Melanotan I varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Melanotan I?
This page links 3 indexed sources for Melanotan I. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.